[Arguments in favor of early treatment of Parkinson's disease with dopaminergic agonists].
Rascol
O
O
Service de Pharmacologie Clinique, INSERM U455, Toulouse.
D000978:Antiparkinson Agents / Q000009:adverse effects; D018491:Dopamine Agonists / Q000009:adverse effects* / Q000494:pharmacology; D006801:Humans; D007980:Levodopa / Q000009:adverse effects; D001523:Mental Disorders / Q000139:chemically induced; D010300:Parkinson Disease / Q000188:drug therapy*; D017447:Receptors, Dopamine D1 / Q000187:drug effects; D017448:Receptors, Dopamine D2 / Q000187:drug effects; D013997:Time Factors; D016896:Treatment Outcome
D000978:Antiparkinson Agents; D018491:Dopamine Agonists; D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D007980:Levodopa